ES2546186T3 - Procedimiento de fabricación de vacunas - Google Patents

Procedimiento de fabricación de vacunas Download PDF

Info

Publication number
ES2546186T3
ES2546186T3 ES08707820.0T ES08707820T ES2546186T3 ES 2546186 T3 ES2546186 T3 ES 2546186T3 ES 08707820 T ES08707820 T ES 08707820T ES 2546186 T3 ES2546186 T3 ES 2546186T3
Authority
ES
Spain
Prior art keywords
sequence seq
saccharide
protein
aliquot
polynucleotide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08707820.0T
Other languages
English (en)
Spanish (es)
Inventor
Ralph Leon Biemans
Pierre Duvivier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Application granted granted Critical
Publication of ES2546186T3 publication Critical patent/ES2546186T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/807—Hapten conjugated with peptide or protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
ES08707820.0T 2007-01-04 2008-01-02 Procedimiento de fabricación de vacunas Active ES2546186T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0700136.5A GB0700136D0 (en) 2007-01-04 2007-01-04 Process for manufacturing vaccines
GB0700136 2007-01-04
PCT/EP2008/050011 WO2008081014A2 (en) 2007-01-04 2008-01-02 Process for manufacturing vaccines

Publications (1)

Publication Number Publication Date
ES2546186T3 true ES2546186T3 (es) 2015-09-21

Family

ID=37801736

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08707820.0T Active ES2546186T3 (es) 2007-01-04 2008-01-02 Procedimiento de fabricación de vacunas

Country Status (7)

Country Link
US (1) US8858955B2 (https=)
EP (1) EP2099487B1 (https=)
JP (1) JP5683815B2 (https=)
CA (1) CA2674007A1 (https=)
ES (1) ES2546186T3 (https=)
GB (1) GB0700136D0 (https=)
WO (1) WO2008081014A2 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20024224A3 (cs) * 2000-06-29 2003-05-14 Glaxosmithkline Biologicals S. A. Farmaceutický prostředek
US7527797B1 (en) 2000-09-01 2009-05-05 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Vibrio cholerae 0139 conjugate vaccines
PE20110072A1 (es) * 2005-06-27 2011-02-04 Glaxosmithkline Biolog Sa Composicion inmunogenica
US20180221466A9 (en) * 2006-06-12 2018-08-09 Glaxosmithkline Biologicals S.A. Use of alpha-toxin for treating and preventing staphylococcus infections
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
JP5658564B2 (ja) 2007-08-31 2015-01-28 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ ブドウ球菌肺疾患および状態に対する免疫に関連した方法および組成物
WO2010014304A1 (en) 2008-07-29 2010-02-04 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
MX2011006922A (es) 2008-12-24 2012-06-12 Netherlands Vaccine Inst Polipeptidos de neumolisina (ply) modificada a partir de streptococcus pneumonia.
HUE026855T2 (en) 2009-04-03 2016-07-28 Univ Chicago Compositions and methods related to protein a (spa) variants
EP3263128A3 (en) 2009-04-14 2018-01-24 GlaxoSmithKline Biologicals S.A. Compositions for immunising against staphylococcus aureus
RU2580299C2 (ru) 2009-06-29 2016-04-10 Дженосеа Биосайенсиз, Инк. Вакцины и композиции, направленные против streptococcus pneumoniae
HUE034251T2 (en) * 2009-10-30 2018-02-28 Glaxosmithkline Biologicals Sa Purification of staphylococcus aureus type 5 and type 8 capsular saccharides
CN102939105B (zh) 2009-12-22 2016-11-16 赛诺菲巴斯德有限公司 免疫原性组合物和相关的方法
CA2803298C (en) 2010-07-02 2020-07-14 The University Of Chicago Compositions and methods related to protein a (spa) variants
WO2012100233A1 (en) 2011-01-20 2012-07-26 Genocea Biosciences, Inc. Vaccines and compositions against streptococcus pneumoniae
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
JP6670106B2 (ja) 2012-04-26 2020-03-18 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ ブドウ球菌コアグラーゼ抗原およびその使用方法
WO2016010081A1 (ja) * 2014-07-18 2016-01-21 一般財団法人化学及血清療法研究所 ウイルス様粒子を含むワクチン
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
CA3010049C (en) * 2016-01-15 2021-10-12 The Chemo-Sero-Therapeutic Research Institute Vaccine containing immobilized virus particles
AU2017218768B2 (en) * 2016-02-12 2022-03-31 Janssen Pharmaceuticals, Inc. Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease
BR112019003992A2 (pt) 2016-09-02 2019-05-28 Sanofi Pasteur Inc vacina contra neisseria meningitidis
CN110366428B (zh) 2016-12-30 2024-05-17 Vaxcyte公司 具有非天然氨基酸的多肽-抗原缀合物
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
US12514914B2 (en) 2019-05-14 2026-01-06 The University Of Chicago Methods and compositions comprising Staphylococcus protein a (SpA) variants
CN114929750B (zh) 2019-09-13 2024-11-22 芝加哥大学 用于治疗葡萄球菌感染的方法和组合物

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0027888B1 (en) * 1979-09-21 1986-04-16 Hitachi, Ltd. Semiconductor switch
DE3040825A1 (de) * 1980-10-30 1982-09-09 Dr. Karl Thomae Gmbh, 7950 Biberach Neues tridekapeptid, verfahren zu seiner herstellung und verwendung
US4673574A (en) * 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
US5180815A (en) * 1988-04-13 1993-01-19 Fuji Photo Film Co., Ltd. Modified protein for carrying hapten
JPH0776236B2 (ja) * 1988-04-13 1995-08-16 富士写真フイルム株式会社 蛋白質修飾物
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
KR920703114A (ko) 1989-07-14 1992-12-17 원본미기재 접합체 백신을 위한 시토킨 및 호르몬 운반체
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
ATE128628T1 (de) 1990-08-13 1995-10-15 American Cyanamid Co Faser-hemagglutinin von bordetella pertussis als träger für konjugierten impfstoff.
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2059692C (en) 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
ES2204900T3 (es) 1992-02-11 2004-05-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Estructura inmuinogena de doble vector.
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
WO1995008348A1 (en) 1993-09-22 1995-03-30 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs
NZ304715A (en) 1995-03-22 1999-07-29 Jackson H M Found Military Med Production of immunogenic constructs using organic cyanylating reagents to activate carbohydrates and then coupling the carbohydrate to a protein, peptide or hapten
TR199701547T1 (xx) 1995-06-07 1998-03-21 Smithkline Beecham Biologicals S.A. Polisakarit antijen protein e�leni�i i�eren a��.
AU1420897A (en) 1996-12-18 1998-07-15 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Conjugate vaccine for (salmonella paratyphi) a
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
US5965714A (en) * 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
US6573245B1 (en) * 1998-04-28 2003-06-03 Galenica Pharmaceuticals, Inc. Modified polysaccharide adjuvant-protein antigen conjugates, the preparation thereof and the use thereof
ATE459373T1 (de) 1999-03-19 2010-03-15 Glaxosmithkline Biolog Sa Impfstoff gegen kapsulare polysaccharide von streptococcus pneumoniae
JP2002541808A (ja) 1999-04-09 2002-12-10 テクラブ， インコーポレイテッド ポリサッカリド結合体ワクチンのための組換えトキシンａタンパク質キャリア
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
WO2002091998A2 (en) 2001-05-11 2002-11-21 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
US20030113350A1 (en) * 2001-09-19 2003-06-19 Fattom Ali I. Glycoconjugate vaccines for use in immune-compromised populations
US20060057160A1 (en) 2002-08-02 2006-03-16 Ralph Biemans Vaccine composition
CA2517439C (en) * 2003-03-07 2013-07-23 Wyeth Holdings Corporation Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
NZ553776A (en) * 2004-09-22 2010-05-28 Glaxosmithkline Biolog Sa Immunogenic composition comprising staphylococcal PNAG and Type 5 and/or 8 Capsular polysaccharide or oligosaccharide.
GB0428394D0 (en) * 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
PE20110072A1 (es) * 2005-06-27 2011-02-04 Glaxosmithkline Biolog Sa Composicion inmunogenica
US7491517B2 (en) 2006-07-19 2009-02-17 Jeeri R Reddy Method of producing meningococcal meningitis vaccine for Neisseria meningitidis serotypes A,C,Y, and W-135
US7935407B2 (en) * 2009-02-23 2011-05-03 Tsung-Wei Chen Decorations

Also Published As

Publication number Publication date
US8858955B2 (en) 2014-10-14
JP2010514817A (ja) 2010-05-06
CA2674007A1 (en) 2008-07-10
EP2099487A2 (en) 2009-09-16
WO2008081014A2 (en) 2008-07-10
US20100143399A1 (en) 2010-06-10
JP5683815B2 (ja) 2015-03-11
WO2008081014A3 (en) 2008-08-21
GB0700136D0 (en) 2007-02-14
EP2099487B1 (en) 2015-06-24

Similar Documents

Publication Publication Date Title
ES2546186T3 (es) Procedimiento de fabricación de vacunas
US20260048112A1 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
AU2021206895B2 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US11872274B2 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
JP5491853B2 (ja) 免疫原性組成物
ES2545221T3 (es) Procedimiento de conjugación de polisacáridos bacterianos con proteínas transportadoras
US12616744B2 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US20240374699A1 (en) Immunogenic Compositions Comprising Conjugated Capsular Saccharide Antigens and Uses Thereof